atenolol has been researched along with Hemangioma Thrombocytopenia Syndrome in 1 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yu, L | 2 |
| Wei, L | 2 |
| Ma, L | 2 |
| Li, L | 2 |
1 other study available for atenolol and Hemangioma Thrombocytopenia Syndrome
| Article | Year |
|---|---|
First report of oral atenolol for treatment of kaposiform hemangioendothelioma, a viable alternative to propranolol.
Topics: Atenolol; Hemangioendothelioma; Humans; Kasabach-Merritt Syndrome; Propranolol; Sarcoma, Kaposi | 2023 |
First report of oral atenolol for treatment of kaposiform hemangioendothelioma, a viable alternative to propranolol.
Topics: Atenolol; Hemangioendothelioma; Humans; Kasabach-Merritt Syndrome; Propranolol; Sarcoma, Kaposi | 2023 |
First report of oral atenolol for treatment of kaposiform hemangioendothelioma, a viable alternative to propranolol.
Topics: Atenolol; Hemangioendothelioma; Humans; Kasabach-Merritt Syndrome; Propranolol; Sarcoma, Kaposi | 2023 |
First report of oral atenolol for treatment of kaposiform hemangioendothelioma, a viable alternative to propranolol.
Topics: Atenolol; Hemangioendothelioma; Humans; Kasabach-Merritt Syndrome; Propranolol; Sarcoma, Kaposi | 2023 |